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ABSTRACT 
Study for pathogenesis of congenital cholesteatoma with comparison of 
proteins expressed in congenital cholesteatoma, acquired cholesteatoma 
and skin of the external auditory canal through proteomics 
 
Seung Ho Shin 
 
Department of Medicine 
The Graduate School, Yonsei University  
 
(Directed by Professor Jae Young Choi) 
 
Congenital cholesteatomas are epithelial lesions which represent invasive growth and 
osteolysis. The incidence consists of 1-5 % in middle ear cholesteatoma, but the 
detection rate is increasing. Especially congenital cholesteatoma can make hearing 
function worse, when it is not properly managed. While the biochemical study of 
acquired cholesteatomas is progressed some degree, the pathogenesis of congenital 
cholesteatomas is nearly unknown. Therefore the biochemical study regarding it is 
necessary now. Considering limitations of genetic study, crossover analysis of proteins 
expressed in congenital cholesteatomas via proteomics and ELISA can give us some 
clue for the understanding of its pathogenesis and make progress in treatment for it. 
Four congenital cholesteatoma matrices, and four samples of normal external auditory 
canal skin and two acquired cholesteatoma were obtained intraoperatively. We 
performed 2D electrophoresis in order to separate the proteins by molecular weight and 
detected. We then analyzed the upregulated spots from the congenital cholesteatoma 
matrices comparing the acquired cholesteatoma specimens through MALDI-TOF MS 
and immunohistochemical staining. 
In the 2D electrophoresis, four samples of congenital cholesteatoma showed very 
similar pattern of proteins expression. Comparing protein expression of acquired 
cholesteatoma and congenital cholesteatoma, some proteins were simultaneously 
expressed and the others not. Similar and different components of protein expression 
between the skin and congenital cholesteatoma sample were identified. The total 
number of spots in the 2-DE image from congenital cholesteatoma, acquired 
cholesteatoma and the skin was 556, 460 and 624. In the congenital and acquired 
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cholesteatoma 326 proteins were simultaneously expressed. Of them, 56 proteins were 
not expressed in the skin. In the skin and congenital cholesteatoma 373 proteins were 
simultaneously expressed. Therefore 127 proteins were expressed only on congenital 
cholesteatoma. Major spots expressed in congenital cholesteatoma gels more than in 
acquired cholesteatoma gels were selected and analyzed, which included titin, PRO2619, 
forkhead transcription activator homolog, ryanodine receptor 2, plectin 1, keratin 10 and 
leucine zipper protein 5. Spots which were densitometrically expressed in congenital 
cholesteatoma gels more than spots of acquired cholesteatoma and were not expressed 
in the skin gels, were analyzed. They were nine spots, which were Ig heavy chain 
variable region (gi|951281), chain A structure of human muscle pyruvate kinase (Pkm2, 
gi|67464392), ribosomal protein L35a isoform CRA_c (gi|119612656), DNA repair and 
recombination protein RAD54B isoform 3 (gi|327532753), protein S100-A7 
(gi|115298657), caspase-5/f (gi|81170715), chain B crystal structure of human caspase-2 
in complex with Acetyl-Leu-Asp-Glu-Ser-Asp-Cho (gi|34810359) and cyclic nucleotide 
gated channel beta 3 (gi|223462173). In immunostaining assay, forkhead transcription 
activator homolog (FKH 5-3), keratin-10 and titin in congenital cholesteatoma specimen 
was identified in contrast to the negative control. 
In this study, we found the proteins expressed in congenital cholesteatoma more than in 
acquired cholesteatoma. Among them, proteins which were not expressed in the skin 
were found. Some of them maybe play an important role in the pathogenesis of 
congenital cholesteatoma. But the function study for them should be continued. 
 
 
 
 
 
 
 
---------------------------------------------------------------------------------------- 
Key words: congenital cholesteatoma, proteomic analysis, acquired 
cholesteatoma  
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I. INTRODUCTION 
Congenital cholesteatomas are epithelial lesions which are characterized with invasive 
growth and osteolysis.
1 
They generally present as a whitish mass behind the tympanic 
membrane (Figure 1) and their incidence accounts for 1~5 % of middle ear 
cholesteatomas. Due to development of endoscope technique their detection rate has 
been recently increasing. They mostly develop from the anterosuperior quadrant of 
mesotympanum and the posterosuperior. The incidence of bilateral congenital 
cholesteatomas accounts for 4 %.
2
 If they progress without proper treatment, they may 
give rise to hearing impairment. For the treatment, excision under general anesthesia is 
required. Figure 2 is a photo of congenital cholesteatoma in the middle ear during 
retroauricular approach. In case they spread out beyond their capsule in the temporal 
bone, wide mastoidectomy and their removal are required. Resulting complications may 
occur. Because affected patients are mostly children, the degree of complications can be 
more serious. Although many animal models for acquired cholesteatoma have been 
suggested, there has been no animal model for congenital cholesteatoma. The 
biochemical study for acquired cholesteatoma has been fairly progressed. Only a small 
number of reports of biochemical study for congenital cholesteatoma has been 
performed until now.
1,3-6
  
It is widely known that in a cell, proteins represent the actual functional molecules and 
mRNA level is not correlated.
7
 To overcome shortcomings of mRNA study, proteomics 
was introduced, which is the large-scale research of proteins, especially their structures 
and functions.
8,9
 To the best of our knowledge, there is no report about proteomics study 
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for congenital cholesteatoma. Using it, we would like to analyze congenital 
cholesteatoma and find key molecules affecting the pathophysiology. 
 
Figure 1. Otoendoscopic photo of congenital cholesteatoma (white arrow) 
behind the tympanic membrane. Congenital cholesteatoma is visible through the 
tympanic membrane via otoendoscopy and located anterior to the malleus 
handle. It is a whitish and ovoid mass like a pearl. 
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Figure 2. Surgical photo of congenital cholesteatoma (white arrow) during a 
retroauricular approach. The congenital cholesteatoma is visible under the 
chorda tympani nerve during surgery. 
 
 
 
II. MATERIALS AND METHODS 
1. Tissue harvest 
Patients were enrolled for the study after they provided written informed consent. We 
obtained approval from the local ethics committee for the use of patient specimens. 
Samples of congenital cholesteatoma, acquired cholesteatoma and the external auditory 
canal skin were harvested from patients (n =6) using a retroauricular approach. They are 
4 children (3 males) with congenital cholesteatoma and 2 adults (2 females) with 
acquired cholesteatoma. Samples of congenital cholesteatoma were harvested without 
damages of its surface (Figure 3). The skin was harvested from 4 children. The samples 
were vigorously washed in order to take out the components of blood. Table 1 shows the 
steps of proteomics which will be described as below. 
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Figure 3. Gross photo of congenital cholesteatoma. The mass, congenital 
cholesteatoma is about 3 mm and has no damage by manual manipulation 
during surgery. For the accurate results, the specimen should be harvested 
without damages by surgical manipulations. 
 
Table 1. 2D electrophoresis and mass spectrum protocol 
Procedure 
1. Preparation of Sample for 2-DE 
2. Isoelectric Focusing (IEF) 
3. Preparation of Second Dimension (2D) Gels 
4. Equilibration of the Sample and Running of the Gel 
5. Gel staining with Coomassie Brilliant Blue G-250 
6. 2D Gel Image Analysis 
7. In-gel Tryptic Digestion 
8. Desalting of Peptides and MALDI Plating 
9. MALDI-TOF and Peptide Mass Fingerprinting 
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2. Preparation of samples for 2-DE 
Each sample was lysed with 2 × sample buffer (250 mM Tris-HCl [pH 6.5], 2 % sodium 
dodecyl sulfate (SDS), 1 % DTT, 0.02 % bromophenol blue, and 10 % glycerol). 
Protein levels were quantified by comparing the absorbance of the lysate with that of 
serially diluted bovine serum albumin (0, 0.2, 0.4, 0.6, 0.8, and 1 mg/ml) in the 
VersaMax ELISA plate reader (Molecular Devices). 
 
3. 2-D electrophoresis 
Isoelectric focusing (IEF) instrumentation, immobilized pH gradient gel (IPG) strips (18 
cm; pH 3-10) and related reagents were purchased from BioRad. IPG strips were 
rehydrated and focused during an automated overnight run in ceramic strip holders 
using 8 h of rehydration, followed by 1 h each at 500, 1000 and 2000 V, followed by 9 h 
20 min at 5000 V for a total of 50 kVh. Immediately prior to loading the focused IPG 
strips on the 2D gels, the strips were incubated in equilibrium buffer (6 M urea, 10% 
sodium dodecylsulfate [SDS], Tris, pH 8.8, glycerol and dithiothreitol [DTT]) for 15 
min, followed by incubation for 15 min in the same solution, except that the DTT was 
replaced by iodoacetamide. 2D SDS polyacrylamide gel electrophoresis (PAGE) 12% 
gels (acrylamide/bis 30% acrylamide/bis, distilled water, 1.5 M Tris/HCl, pH 8.8, 10% 
SDS, 10% ammonium persulfate, 0.1% tetra-methyl-ethylenediamine) were cast with 
glass plate sandwiches from Bio-Rad Protean II xi chambers (20X20 cm2; 1.5-mm 
thick). The SDS equilibrated IPGs were sealed on top of the 2D gels using 0.5% agarose 
containing bromophenol blue. SDS gels were run until the tracking dye was within 1 cm 
of the gel bottom. Colloidal CBB staining was used to visualize proteins and gel images 
were scanned. Silver staining was conducted as described by Hochstrasser et al.
10
 
Stained 2D gels were analyzed using Melanie III 2D PAGE analysis software (Genebio, 
Geneva, Switzerland). Congenital cholesteatoma matrix gels were compared with three 
normal external auditory canal skin gels and acquired cholesteatoma gels. Spots 
upregulated in congenital cholesteatoma gels, or only detected in congenital 
cholesteatoma densitometrically were selected and analyzed. 
  
8 
 
4. Identification of protein by matrix-assisted laser desorption/ionization - 
time of flight mass spectrometer (MALDI-TOF MS) 
For 2-D gel mapping, major proteins were identified by mass finger printing or by 
matching with various internal 2-DE maps. Protein spots excised from 2-DE gels were 
destained, reduced, alkylated and digested with trypsin (Promega, Madison, WI) as 
previously described.
11
 For MALDI-TOF MS analysis, the peptides were concentrated 
by a POROS R2, Oligo R3 column (Applied Biosystems, Foster city, CA, USA). After 
washing the column with 70% acetonitrile, 100% acetonitrile and then 50 mM 
ammonium bicarbonate, samples were applied to the R2, R3 column and eluted with 
cyano-4-hydroxycinamic acid (CHCA) (Sigma, St. Louis, MO) dissolved in 70% 
acetonitrile and 2% formic acid onto the MALDI plate (Opti-TOF™ 384-well Insert, 
Applied Biosystems).
12
 MALDI-TOF MS was performed on 4800 MALDI-TOF/TOF™ 
Analyzer (Applied Biosystems) equipped with a 355-nm Nd:YAG laser. The pressure in 
the TOF analyzer is approximately 7.6e-07 Torr. The mass spectra were obtained in the 
reflectron mode with an accelerating voltage of 20 kV and sum from either 500 laser 
pulses and calibrated using the 4700 calibration mixture (Applied Biosystems). Proteins 
were identified from the peptide mass maps using MASCOT 
(http://www.matrixscience.com/search_form_select.html), which searched the protein 
databases of the NCBI non-redundant human database containing 115818 entries 
(downloaded on 05/09/2009).  
A. Analysis of upregulated proteins in congenital cholesteatoma comparing 
acquired cholesteatoma 
Top ten spots of which were expressed in congenital cholesteatoma gels 
more than paired spots in acquired cholesteatoma gels were selected and 
analyzed, 
B. Analysis of major spots expressed only in congenital cholesteatoma 
To find the proteins expressed only in congenital cholesteatoma, paired 
spots in skin gels were excluded among the upregulated spots in 
congenital cholesteatoma gels. Top nine spots were selected and 
analyzed. 
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5. Immunohistochemical staining 
To examine the expression pattern of target proteins, tissues were fixed with 4% 
paraformaldehyde for 24 hours and then dehydrated and embedded in paraffin. Paraffin 
blocks were sectioned into 5-µm-thick slices and fixed with a chilled 1:1 mixture of 
methanol and acetone for 5 minutes after pretreatment with 0.3% H2O2 for 20 minutes 
at room temperature. Slides were treated with 1:600 normal rabbit serum for 20 minutes 
to block nonspecific reactions and then incubated with a monoclonal mouse antibody 
against target proteins including Titin (HPA007042, sigma
®
), forkhead transcription 
activator homolog (clone FKH 5-3, human (fragment), AHP933, AbD Serotec
®
) and  
keratin10 (ab97764, abcam
®
). The slides were then incubated with biotinylated 
antimouse rabbit immunoglobulin G (1:200; Vector Laboratories
®
, Burlingame, CA, 
USA). Peroxidase was attached to the secondary antibody by avidin-biotin peroxidase 
complex formation. Specimens were incubated in diaminobenzidine tetrahydrochloride 
to detect primary antibody binding sites. 
 
 
 
III. RESULTS 
1. 2D electrophoresis of protein expression in samples of congenital 
cholesteatoma, acquired cholesteatoma and the skin of the external 
auditory canal 
In the 2D electrophoresis, four samples of congenital cholesteatoma showed very 
similar pattern of proteins expression (Figure 4). Comparing protein expression of 
acquired cholesteatoma and congenital cholesteatoma, some proteins were 
simultaneously expressed and the others not (Figure 5). Similar and different 
components of protein expression between the skin and congenital cholesteatoma 
sample were identified (Figure 6). To sum it up, we could make a diagram (Figure 7), 
which meant the distribution of expressed proteins among the samples. The proteins 
which expressed only in congenital cholesteatoma maybe play an important role in the 
pathogenesis of congenital cholesteatoma. Also among proteins which simultaneously 
expressed in congenital and acquired cholesteatomas, overexpressed ones maybe effect 
on the pathogenesis. 
10 
 
 
Figure 4. 2D electrophoresis with congenital cholesteatoma in 4 patients (A-D). 
In the Figure A-D, the similar pattern (red circles) is visible. This means that 
congenital cholesteatoma in each patients shows same pattern of proteins 
expression in 2D electrophoresis.  
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Figure 5. 2D electrophoresis with acquired (A) and congenital (B) 
cholesteatomas. Red circles shows similar pattern of proteins expression 
between acquired and congenital cholesteatomas and blue circle means the 
proteins expressed in acquired cholesteatoma. 
 
Figure 6. 2D electrophoresis with the skin of the external auditory canal (A) 
and congenital cholesteatomas (B). Two of 2D electrophoresis show similar 
pattern in some region and different in the other. Number of spots in congenital 
cholesteatoma is less than in the skin. 
12 
 
 
Figure 7. Distribution of proteins from the congenital and acquired 
cholesteatomas and the skin. Based on the Figure 4, 5 and 6, it is inferred that 
distribution of proteins is as above diagram. That is, 3 specimens have common 
proteins and also their own. 
 
2. Identification of proteins in congenital cholesteatoma, acquired 
cholesteatoma and the skin 
MALDI-TOF MS was performed to identify the proteins represented by each spot in the 
2-DE of congenial cholesteatoma 1. The total number of spots in the 2-DE image from 
congenital cholesteatoma, acquired cholesteatoma and the skin was 556, 460 and 624 
(Figure 8). In the congenital and acquired cholesteatoma 326 proteins were 
simultaneously expressed. Of them, 56 proteins were not expressed in the skin. In the 
skin and congenital cholesteatoma 373 proteins were simultaneously expressed. 
Therefore 127 proteins were expressed only on congenital cholesteatoma.  
Ten major spots densitometrically expressed in the congenital cholesteatoma gel more 
than in the acquired cholesteatoma gels were selected and analyzed, which included titin 
(gi|407139), PRO2619 (gi|11493459), forkhead transcription activator homolog 
(gi|477361), ryanodine receptor 2 isoform CRA_c (gi|119590477), plectin 1 
intermediate filament binding protein (gi|119602578), , keratin 10 (epidermolytic 
hyperkeratosis; keratosis palmaris et plantaris, gi|119581085), keratin 10 (gi|186629), 
13 
 
keratin 10 (gi|119581085), titin (gi|407139) and leucine zipper protein 5 isoform 
CRA_b (gi|119624991). These results are shown in Figure 9 and Tables 2.  
 
Figure 8. Types of proteins expressed in congenital and acquired 
cholesteatomas, and external auditory canal skin. 
Skin: proteins expressed in external auditory canal skins, Cong: proteins 
expressed in congenital cholesteatomas, Acq: proteins expressed in acquired 
cholesteatoma 
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Figure 9. 2-DE image of ten major spots expressed in congenital 
cholesteatoma.   
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Table 2. Protein names of 10 major spots expressed in congenital cholesteatoma 
gel more than in acquired cholesteatoma gel 
Group No. Protein name (gray p>0.05) Mr PI % 
coverage 
Matched 
peptide 
number 
112 68 for gi|407139, titin 524823 8.06 10 28 
127 66 for gi|11493459, PRO2619) 58513 5.96 21 15 
128 66 for gi|477361, clone FKH 5-3 12861 10.06 66 5 
132 67 for gi|119590477, ryanodine receptor 2 
(cardiac) isoform CRA_c 
568496 5.69 10 28 
272 67 for gi|119602578, plectin 1  
intermediate filament binding protein 
isoform CRA_c 
290791 5.62 14 41 
294 81 for gi|119581085, keratin 10 63536 5.13 28 16 
385 66 for gi|186629, keratin 10 39832 4.72 31 10 
447 77 for gi|119581085, keratin 10 63536 5.13 30 16 
535 67 for gi|407139, titin 524823 8.06 11 29 
587 66 for gi|119624991, leucine zipper 
protein 5  isoform CRA_b 
9456 11.70 72 8 
Mr: nominal mass, FKH: Forkhead transcriptional factor, PI: calculated pI value, % coverage: sequence 
coverage, Matched peptide number: number of mass values matched 
 
Spots which were densitometrically upregulated in congenital cholesteatoma gels 
comparing spots of acquired cholesteatoma and simultaneously were not expressed in 
the skin gels, were analyzed. They were nine spots, which were Ig heavy chain variable 
region (gi|951281), chain A structure of human muscle pyruvate kinase (Pkm2, 
gi|67464392), ribosomal protein L35a isoform CRA_c (gi|119612656), DNA repair and 
recombination protein RAD54B isoform 3 (gi|327532753), protein S100-A7 
(gi|115298657), caspase-5/f (gi|81170715), chain B crystal structure of human caspase-2 
in complex with Acetyl-Leu-Asp-Glu-Ser-Asp-Cho (gi|34810359) and cyclic nucleotide 
gated channel beta 3 (gi|223462173). These results are shown in Figure 10 and Tables 3. 
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Figure 10. 2-DE image of 9 major spots expressed only in congenital 
cholesteatoma.  
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Table 3. Protein names of 9 major spots major spots which were expressed in 
the congenital cholesteatoma gel more than in the acquired cholesteatoma gel 
and not expressed in the skin gel. 
 
Group No. Protein name (gray p>0.05) Mr PI % 
coverage 
Matched 
peptide 
number 
46 35 for gi|951281, Ig heavy chain variable 
region 
14247 9.44 55 4 
143 66 for gi|67464392, Chain A Structure Of 
Human Muscle Pyruvate Kinase (Pkm2)  
60277 8.22 25 11 
277 66 for gi|119612656, ribosomal protein 
L35a, isoform CRA_c 
16121 11.19 52 9 
516 66 for gi|327532753, DNA repair and 
recombination protein RAD54B isoform 3 
83786 8.03 31 13 
523 72 for gi|115298657, protein S100-A7 11578 6.28 68 10 
538 68 for gi|81170715, caspase-5/f 51785 9.28 31 9 
550 34 for gi|34810359, Chain B Crystal 
Structure Of Human Caspase-2 In 
Complex With Acetyl- 
Leu-Asp-Glu-Ser-Asp-Cho 
12235 8.98 58 5 
660 68 for gi|223462173, Cyclic nucleotide 
gated channel beta 3 
92633 8.37 20 12 
673 66 for gi|55960204, UBX domain protein 
11 
18324 8.56 22 8 
Mr: nominal mass, PI: calculated pI value, % coverage: sequence coverage, Matched peptide number: number 
of mass values matched 
 
 
3. Immunohistochemial staining 
Immunolocalization demonstrated that Forkhead transcriptional factor homolog (FHK 
5-3) localized in the cell membrane and cytoplasm in all layers of keratinocytes of 
congenital cholesteatoma in contrast to the negative control. Figure 11. A shows the 
distribution of Forkhead transcriptional factor homolog protein in keratinocytes. Control 
studies using normal IgG instead of primary antibody all showed no staining in 
congenital cholesteatoma. Figure 11. B shows the negative control. Also keratin-10 and 
titin were also identified in congenital cholesteatoma specimen. 
18 
 
 
 
 
Figure 11. Immunocytochemical staining of congenital cholesteatoma using 
monoclonal anti-Forkhead transcriptional factor homolog (FKH 5-3) antibody. 
A. A positive brown staining is visible in the keratinocytes in the congenital 
cholesteatoma epithelium, B. Negative control.  
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IV. DISCUSSION 
Definition and incidence of congenital cholesteatoma 
In 1953, the first case of congenital cholesteatoma was reported by Howard House.
13
 
Derlacki and Clemis presented 6 cases of congenital cholesteatoma and established the 
clinical criteria for the diagnosis.
14
 These includes a whitish mass medial to an intact 
tympanic membrane, a normal pars tensa and flaccida, and ho history of otorrhea, 
perforation or previous otologic procedure.
15
 
The detection rate of congenital cholesteatomas originated from the middle ear cavity has 
been increased and accounts for 2% to 5%.
16
 Therefore many otologists are becoming 
interested in them. Based on the position and stage of them, their symptoms and signs 
include conductive hearing loss, sensorineural hearing loss, facial palsy, labyrinthitis and 
intracranial complications.  
 
Proposed pathophysiology 
The pathophysiology of congenital cholesteatomas of the middle ear is still controversial. 
Suggested mechanisms are epithelial rests from faulty embryogenesis, invagination of 
squamous epithelium, implantation, or metaplasia of normal epithelium.
15
  
Among them, epithelial rest theory is the most commonly accepted. Teed reported a small 
splinter of epidermal cells which showed cornification and desquamation and was in the 
dorsolateral pole of the tympanum, just medial to the neck of the malleus in 5.5-month 
fetus. He trusted that normally epidermal cells become transformed into epithelial cells but 
sometimes they persist in their ectodermal quality and produce skin, which finally result in 
cholesteatoma.
17
 In 1997, Kayhan et al investigated 226 fetal, neonatal and children’s 
temporal bones.
18
 They noticed 25 epidermoid formations without keratinization in fetal, 
infantal and children’s temporal bones. 
Invagination theory, that is, migration of normal squamous epithelium from the external 
auditory canal through the annulus and into the middle ear as the pathophysiology of 
congenital cholesteatoma was suggested by Ruedi and Aimi.
19,20
 Their theory is that due to 
small inflammatory injury of the epithelium, invagination of the epithelium can occur and 
form a congenital cholesteatoma. It doesn’t have been supported by histopathologic 
evidence, but would explain lesions not located in the anterior superior quadrant of the 
tympanic membraine.
15
 
Implantation theory was proposed by Friedberg and Sheehy, which was that implantation 
of squamous epithelium by trauma and subsequent healing of the tympanic membrane 
20 
 
resulted in the formation of congenital cholesteatoma.
21,22
 It may explain some cases of 
congenital cholesteatoma, which arises from many different sites but is incompatible with 
the definition of congenital cholesteatoma.  
Metaplasia theory was advocated by Sade.
6
 It means that the inflamed middle ear 
epithelium is converted into the squamous epithelium, but cannot explain the high 
frequency of cholesteatoma lesions in the anterior superior quadrant of middle ear. 
 
Animal Model for cholesteatoma 
Many animal models for acquired cholesteatoma were reported in the literature. Ruedi 
reported that cholesteatoma was induced due to application of mixture with talc and fibrin 
into the inner surface of the tympanic membrane in the Guinea pig model.
20
 Friedmann 
observed the external auditory canal skin moved into the middle ear through the 
perforation after injection of bacteria into the tympanic cavity in the Guinea pig model.
23
 
Abramson, Jackson and Lim demonstrated that cholesteatoma occurred after the fragment 
of the skin was implanted into the middle ear of guinea pigs and cat model, 
respectively.
24,25
 Steinbach reported the rabbit model, in which he observed cholesteatoma 
growth secondary to the operative closure of the external auditory canal.
26
 Wright 
suggested the chinchilla middle ear model in which cholesteatoma appeared after injection 
of the propylene glycol into the middle ear.
27
 Wolfman and Chole made Mongolian gerbil 
model in which they showed retraction pocket formation after electrocauterization of the 
Eustachian tube. However, there has been no animal model for congenital cholesteatoma 
so far.  
 
Current biochemical study’s advances for congenital cholesteatoma 
Though modern biochemical research for many diseases has been well developed, the 
exact pathogenic molecular mechanism of congenital cholesteatoma remains unclear.  
In 1992, Immunohistochemical study to determine the pattern of cytokeratin expression in 
congenital and acquired cholesteatoma was reported By Broekaert et al. They showed 
same cytokeratin expression.
28
 In addition, Olszewska et al reported the same result with 
Broekaert.
3
 
In 1993, number of dendritic cells in acquired and congenital cholesteatoma was compared 
by Frankel et al.
5
 They observed congenital cholesteatoma specimen significantly had 
smaller number of dendritic cells than acquired cholesteatoma did and stated that 
congenital cholesteatomas are pathologically different entity from acquired cholesteatoma.  
21 
 
Ras protein modulating cellular proliferation, transformation and differentiation was 
identified in both congenital and acquired cholesteatomas by Huang et al.
29
 They think it 
might play a pivotal role in a signal transduction cascade.  
Expression of P53 tumor suppressor gene regulating cell cycle control and apoptosis in 
acquired and congenital cholesteatoma was elevated 9 to 20 folds when compared to the 
expression of p53 in normal external auditory canal skin.
30
 
Tumor necrosis factor-alpha regulating bone resorption and cell infiltration was studied, of 
which expression was increased in both congenital and acquired cholesteatoma as 
compared to normal skin.
31
  
Kojima et al studied about telomere length in both cholesteatomas and found that telomere 
length of congenital cholesteatoma was shorter than one of normal skin and the length of 
acquired cholesteatoma almost the same as in the normal external ear canal skin.
32
 This 
study support the epithelial rest theory which was described above. 
The decreased p27 protein levels in both cholesteatomas were reported. The authors 
concluded that its role was unclear but its level could influence the proliferative state.
33
  
Park et al studied p63 and survivin.
34
 p63 overexpression which was related to actively 
proliferative cells was observed in congenital cholesteatoma. Survivin, a potential 
modulator of kerationocyte apoptosis is was noted focally in the basal layer or not noted at 
all in congenital cholesteatoma. The authors concluded that the theory that congenital 
cholesteatoma originates from vestigial fetal tissue or aberrant tissue. 
IL-17 which induces the production of inflammatory cytokines such as IL-1, TNF-alpha 
and IL-l was analyzed for congenital cholesteatoma by Haruyama et al.
35
 They reported 
IL-17-driven pathology was found in both cholesteatoma. 
Ki-67 in congenital cholesteatoma was studied by Sikka et al.
36
 It is widely used 
proliferation marker in tumors. The authors tried to find the relationship between Ki-67 
and aggressiveness of acquired and congenital cholesteatoma but there was no difference 
between them.  
In 2013, Olszewska et al reported that p21 and p53 expression in congenital 
cholesteatoma.
1
 They are related to apoptosis. The authors concluded that upregulation of 
p21 protein is expected to a significant role in congenital cholesteatoma development. 
In summary, current trends of biochemical study for congenital cholesteatoma has focused 
on the apoptosis of keratinocytes. 
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Present study 
Among the proposed theories as described before, we focused on the epithelial cell rest 
theory. Michales et al investigated 68 fetal temporal bones, found the epithelial cell rest 
from the middle ears only before the 33
rd
 week of gestation and speculated they would 
disappear or decrease in size with increasing age.
37-40
 On the contrary, Kayhan et al 
examined 226 fetal temporal bones and found the size of epithelial cell rest increased with 
increasing age. They concluded an epithelial cell rest may cease in late fetal life but may 
remain in some. Therefore it is thought that there is an unknown mechanism which may 
influence on continuance of an epithelial cell rest after 33
rd
 weeks of gestation.  
To find unknown mechanism, proteomics study was used in this study. It is a useful tool 
for separating proteins and quantitatively comparing changes in protein components 
between each tissues.
41
 For comparison of the materials, congenital cholesteatoma, the skin 
of the external auditory canal, and acquired cholesteatoma were selected. With two 
dimensional gel electrophoresis, proteins were separated. The pattern of protein 
distribution among 4 congenital cholesteatomas after gel electrophoresis was relatively 
similar contrary to expectations (Figure 4). In the present study, 127 proteins expressed 
only in congenital cholesteatoma were found.  
Top ten upregulated proteins which were found in congenital cholesteatoma and expressed 
more than in acquired cholesteatoma, were selected for MALDI-TOF and MASCOT 
analysis. They were revealed as titin (gi|407139), PRO2619 (gi|11493459), forkhead 
transcription activator homolog (gi|477361), ryanodine receptor 2 (cardiac), isoform 
CRA_c (gi|119590477), plectin 1, intermediate filament binding protein 
(gi|119602578), , keratin 10 (epidermolytic hyperkeratosis; keratosis palmaris et 
plantaris, gi|119581085), keratin 10 (gi|186629), keratin 10 (gi|119581085), titin 
(gi|407139) and leucine zipper protein 5 isoform CRA_b (gi|119624991). Among them, 
keratin components were excluded for candidate proteins. It is know that titin seems 
play a role in chromosome condensation and chromosome segregation during mitosis.
42
 
ryanodine receptor 2 is calcium channel that mediates the release of Ca2+ from the 
sarcoplasmic reticulum into the cytoplasm and plays a key role in triggering cardiac 
muscle contraction.
43,44
 There has been no report it is related to keratinocytes. Leucine 
zipper protein has a common three-dimensional structural motif in proteins. These 
motifs are usually found as part of a DNA-binding domain in various transcription 
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factors, and are therefore involved in regulating gene expression.
45
 Plectin 1 is interlinks 
intermediate filaments with microtubules and microfilaments and anchors intermediate 
filaments to desmosomes or hemidesmosomes.
46,47
  
Forkhead (FKH) gene is a new family of transcriptional factors that regulate 
development and are related to immune response.
48
 Some of them regulate T cells and B 
cells and promote and/or maintain chronic inflammation by preserving inflammatory 
leukocyte survival and/or otherwise promoting the expression of inflammatory target 
genes, at least in some cell types such as neutrophils.
49
 There is a report that forkhead 
transcription factors can influence on cholesteatoma growth and proliferation via 
Akt/PKB pathway activation and subsequent apoptosis inhibition.
50
 Among its family, it 
is known that FKH 5-3 was found in blood cells including CML cell line K562 and in 
the Jurkat T-cell leukemia line but not normal human marrow.
51,52
 It is related to early 
hematopoietic development.48 There is no report that FKH 5-3 is associated with other 
tissues. 
Top nine upregulated proteins which were found in congenital cholesteatoma and 
expressed more than in acquired cholesteatoma but were not expressed in the skin 
specimen, were selected for MALDI-TOF and MASCOT analysis. They were revealed 
as Ig heavy chain variable region (gi|951281), chain A structure of human muscle 
pyruvate kinase (Pkm2, gi|67464392), ribosomal protein L35a isoform CRA_c 
(gi|119612656), DNA repair and recombination protein RAD54B isoform 3 
(gi|327532753), protein S100-A7 (gi|115298657), caspase-5/f (gi|81170715), chain B 
crystal structure of human caspase-2 in complex with 
Acetyl-Leu-Asp-Glu-Ser-Asp-Cho (gi|34810359) and cyclic nucleotide gated channel 
beta 3 (gi|223462173). It is thought that Ig heavy chain variable region, ribosomal 
protein L35a isoform CRA_c, crystal structure of human caspase-2 in complex with 
Acetyl-Leu-Asp-Glu-Ser-Asp-Cho, cyclic nucleotide gated channel beta 3 and UBX 
domain protein 11 may not related to the pathophysiology for congenital cholesteatoma 
based on the proteomics database. Pkm2 is a glycolytic enzyme that catalyzes the 
transfer of a phosphoryl group from phosphoenolpyruvate (PEP) to ADP, 
generating ATP. It plays a general role in caspase independent cell death of tumor 
cells. The transition between the 2 forms contributes to the control of glycolysis 
and is important for tumor cell proliferation and survival.
53-55
 DNA repair and 
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recombination protein RAD54B isoform 3 involves in DNA repair and mitotic 
recombination.
56,57
 Protein S100-A7 is a member of the S100 family of proteins 
containing 2 EF-hand calcium-binding motifs. S100 proteins involved the regulation of 
a number of cellular processes such as cell cycle progression and differentiation.
58
 This 
protein is markedly over-expressed in the skin lesions of psoriatic patients. It is found in 
fetal ear and the skin and has antimicrobial properties.
59
 Therefore it may be related to 
the epithelial rest theory. Caspase-5/f is a mediator of programmed cell death, that is, 
apoptosis.
60
 As mentioned above, the pathophysiology of cholesteatoma recently 
proposed is apoptosis. Therefore caspase-5/f may have an important role for the 
pathophysiology.  
In summary, several candidate proteins were identified but further study is required in 
order to find the exact proteins which act as a key protein in the pathophysiology of 
congenital cholesteatoma. 
 
 
 
V. CONCLUSION 
In this study, we found the proteins expressed only in congenital cholesteatoma in 
contrast with acquired cholesteatoma or the skin. They maybe play an important role in 
the pathogenesis of congenital cholesteatoma. But the function study for them should be 
continued. 
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ABSTRACT (IN KOREAN) 
프로테오믹스 분석을 통해 선천성 진주종, 후천성 진주종 및 
외이도 피부에 발현되는 단백질의 비교로 선천성 진주종의 
병인에 관한 연구 
 
<지도교수 최  재  영> 
 
연세대학교 대학원 의학과 
 
신  승  호 
 
선천성 진주종은 파괴적인 성장과 골용해를 보이는 상피성 병변이다. 
발생률은 중이 진주종의 1-5%이지만, 발견률이 증가 추세이다. 선천성 
진주종은 적절히 치료되지 않는 경우, 특히 청력을 손상시킬 수 있다. 
후천성 진주종의 분자화학적 연구가 어느 정도 진행되어 있으나, 
선천성 진주종에 대한 연구는 매우 적다. 그래서 선천성 진주종에 
대한 분자화학적 연구가 현재 필요하다. 유전학적 연구의 제한점을 
고려했을 때, 프로테오믹스를 이용해 선천성 진주종에 발현되는 
단백질의 교차연구가 선천성 진주종의 병인을 이해와 치료의 발전에 
도움을 줄 수 있을 것이다. 
수술 중 얻은 선천성 진주종 4례와 외이도 피부 4례, 2례의 후천성 
진주종이 사용되었다. 2차원 전기영동을 통해 분자량에 따라 단백질을 
분리하였다. 분리된 단백질 중 선천성 진주종에서만 많이 발현되는 
10개의 단백질을 MALDI-TOF MS와 면역염색을 통해 분석하였다. 
결과: 2D 전기 영동에서 선천성 진주종 4례는 매우 비슷한 단백질 
분포를 보였다. 후천성 진주종과 선천성 진주종의 발현된 단백질을 
비교했을 때, 어떤 단백질은 공통으로 발현이 되었고 다른 단백질은 
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그렇지 않았다. 선천성 진주종과 외이도피부에 발현된 단백질 역시 
공통적으로 발현된 단백질과 그렇지 않은 단백질로 구분이 되었다. 
선천성 진주종, 후천성 진주종 그리고 외이도 피부에서 발견된 
단백질의 개수는 각각 556, 460 그리고 624 개이다. 선천성 진주종과 
후천성 진주종에서 동시에 발견된 단백질의 개수는 326개이며 이 중 
56개의 단백질은 외이도 피부에서 발현되지 않았다. 피부와 선천성 
진주종에서 동시에 발견된 단백질의 개수는 373개이다. 종합하면 
127개의 단백질이 선천성 진주종에서만 발견이 되었다. 후천성 
진주종에서 발현된 것보다 더 많이 발현된 선천성 진주종 상위 
10개의 단백질은 titin (gi|407139), PRO2619 (gi|11493459), forkhead 
transcription activator homolog (gi|477361), ryanodine receptor 2 (cardiac), 
isoform CRA_c (gi|119590477), plectin 1, intermediate filament binding protein 
(gi|119602578), keratin 10 (epidermolytic hyperkeratosis; keratosis palmaris et 
plantaris, gi|119581085), keratin 10 (gi|186629), keratin 10 (gi|119581085), titin 
(gi|407139), leucine zipper protein 5 그리고 isoform CRA_b 
(gi|119624991)이었다. 또, 피부에서는 발현되지 않고 후천성 
진주종보다 과발현된 선천성 진주종의 단백질 9개를 분석한 결과 Ig 
heavy chain variable region (gi|951281), chain A structure of human muscle 
pyruvate kinase (Pkm2, gi|67464392), ribosomal protein L35a isoform CRA_c 
(gi|119612656), DNA repair and recombination protein RAD54B isoform 3 
(gi|327532753), protein S100-A7 (gi|115298657), caspase-5/f (gi|81170715), 
chain B crystal structure of human caspase-2 in complex with 
Acetyl-Leu-Asp-Glu-Ser-Asp-Cho (gi|34810359), cyclic nucleotide gated 
channel beta 3 (gi|223462173) 등이 확인되었다.  
면역염색상 forkhead transcription activator homolog (FKH 5-3), keratin-10, 
titin 등이 선천성 진주종 시료에서 확인이 되었다.  
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이 연구에서 후천성 진주종과 외이도 피부와는 달리 선천성 
진주종에서만 발현되는 단백질들을 발견하였다. 이 단백질들 중 
일부는 선천성 진주종의 병태생리에 중요한 역할을 할 것으로 보인다. 
그러나 이들에 대한 기능적 연구를 더 이루어져야 한다. 
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